Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
Kodiak Sciences announced its third quarter 2026 financial results and recent business highlights on Friday, November 13, 2026. The company trades on the Nasdaq under ticker KOD and on the Munich exchange under K27. The announcement follows the presentation of phase 3 DAYBREAK trial data for Zenkuda and tabirafusp alfa tedromer at the American Academy of Ophthalmology meeting in New Orleans, where David A. Eichenbaum of Retina Vitreous Associates of Florida highlighted that 54% of Zenkuda-treated patients achieved a six-month treatment interval.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Kodiak Sciences trades on Nasdaq under ticker KOD and on the Munich exchange under K27.
- ✓ David A. Eichenbaum of Retina Vitreous Associates of Florida presented DAYBREAK trial data at the American Academy of Ophthalmology meeting in New Orleans.
- ✓ 54% of patients treated with Zenkuda achieved a six-month duration between treatments without additional intervention.
What changed
Kodiak Sciences released its Q3 2026 financial results and business highlights announcement on November 13, 2026, adding a quarterly financial update to the previously reported DAYBREAK trial data presentation.
Live updates
-
Kodiak Sciences reports Q3 2026 results and business highlights
Kodiak Sciences announced its third quarter 2026 financial results and recent business highlights on Friday, November 13, 2026. The company trades on the Nasdaq under ticker KOD and on the Munich exchange under K27. The announcement follows the presentation of phase 3 DAYBREAK trial data for Zenkuda and tabirafusp alfa tedromer at the American Academy of Ophthalmology meeting in New Orleans, where David A. Eichenbaum of Retina Vitreous Associates of Florida highlighted that 54% of Zenkuda-treated patients achieved a six-month treatment interval.
Why it matters
Kodiak Sciences is advancing two wet age-related macular degeneration candidates, Zenkuda and tabirafusp alfa tedromer, through late-stage clinical development. The DAYBREAK trial results presented at AAO 2026 position Zenkuda as a potential extended-duration alternative to Regeneron's Eylea, the current standard of care. Investors are monitoring whether the six-month durability data translates into commercial differentiation and market share. The Q3 financial update provides insight into the company's cash runway as it approaches potential regulatory milestones.
What is confirmed
- Kodiak Sciences trades on Nasdaq under ticker KOD and on the Munich exchange under K27.
- David A. Eichenbaum of Retina Vitreous Associates of Florida presented DAYBREAK trial data at the American Academy of Ophthalmology meeting in New Orleans.
- 54% of patients treated with Zenkuda achieved a six-month duration between treatments without additional intervention.
What to watch next
- Regulatory filing timeline for Zenkuda based on DAYBREAK results
- Cash runway and funding needs disclosed in Q3 2026 financials
- Tabirafusp alfa tedromer phase 3 data readout and comparison to Zenkuda
confidence 80%Sources used for this update (3)
- www.marketbeat.com — Top Biotech Stocks To Research - October 14th | MarketBeat
- www.wallstreetzen.com — Sandisk Stock Price Today (NASDAQ: SNDK) Quote, Market Cap, Chart
- finance.yahoo.com — Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
-
Kodiak Sciences Presents DAYBREAK Trial Data for Wet AMD
Kodiak Sciences showcases phase 3 DAYBREAK clinical trial results for its wet age-related macular degeneration treatments at the American Academy of Ophthalmology meeting in New Orleans. David A. Eichenbaum of Retina Vitreous Associates of Florida highlights findings for Zenkuda and tabirafusp alfa tedromer evaluated against Regeneron's Eylea. Eichenbaum points out that 54% of patients treated with Zenkuda achieved a six-month duration between treatments without additional intervention. Financial markets and shareholders track company stock performance on the Nasdaq and Munich exchanges under tickers KOD and K27.
Why it matters
The presentation of the DAYBREAK trial offers critical clinical performance data for Kodiak Sciences within the competitive ophthalmology therapeutics market. Analysts and investors monitor these medical milestones to assess the commercial viability of Zenkuda and KSI-501 against established treatments like Eylea. These disclosures directly influence market valuations and share activity across international public exchanges.
What is confirmed
- David A. Eichenbaum highlighted phase 3 DAYBREAK trial data on Zenkuda for wet age-related macular degeneration at the American Academy of Ophthalmology meeting in New Orleans.
- Researchers assessed Zenkuda, known as tarcocimab tedromer, and KSI-501, known as tabirafusp alfa tedromer from Kodiak Sciences, against Regeneron's Eylea in the DAYBREAK clinical trial.
- Fifty-four percent of patients who received Zenkuda went out as far as six months without needing treatment.
What to watch next
- Additional long-term efficacy and safety data releases from the DAYBREAK trial
- Subsequent regulatory filings or commercialization updates from Kodiak Sciences regarding Zenkuda and KSI-501
confidence 100%Sources used for this update (2)
- www.linkoph.com — Zenkuda for wet AMD ‘impressive and encouraging’ at 1 year
- www.healio.com — Zenkuda for wet AMD ‘impressive and encouraging’ at 1 year
-
Kodiak Sciences Stock Trades on Major Exchanges Following Trial Success
Kodiak Sciences trades publicly on the Nasdaq and Munich exchanges under the ticker symbols KOD and K27 respectively. Investors and analysts continue to track financial data, quotes, and market performance for the company following the phase III trial results of its wet AMD treatment. The stock price reflects ongoing market attention as financial platforms provide charts, analysis, and historical data for shareholders evaluating the pharmaceutical firm's clinical milestones.
Why it matters
Public stock listings allow investors to monitor market valuation as clinical developments unfold. Financial tracking on major exchanges provides visibility into how market participants assess corporate assets and drug development pipelines.
What is confirmed
- Kodiak Sciences Inc. trades on the Nasdaq under the stock ticker KOD.
- Kodiak Sciences Inc. is listed on the Munich exchange under the ticker K27.
What to watch next
- Updates to financial forecasts and stock analysis on market tracking platforms
- Quarterly financial reports and corporate updates from Kodiak Sciences
confidence 100%Sources used for this update (3)
- www.marketscreener.com — Kodiak Sciences Inc. Stock (KOD) - Quote Nasdaq- MarketScreener
- markets.ft.com — Kodiak Sciences Inc., K27:MUN summary - FT.com
- stockanalysis.com — Kodiak Sciences (FRA:K27) Stock Price, Chart & News
-
Kodiak Sciences soars on positive Zenkuda trial results
Kodiak Sciences' stock rose after Zenkuda, also known as tabirafusp-ted, met primary endpoints in a phase III wet age-related macular degeneration trial. The treatment showed vision gains non-inferior to aflibercept at one year. This development places Zenkuda in direct competition with the current standard of care for wet AMD. Investors are weighing the clinical efficacy and dosing intervals.
Why it matters
The phase III DAYBREAK trial results are crucial for Kodiak Sciences as they position Zenkuda as a potential competitor to existing treatments for wet AMD. Wet AMD is a leading cause of vision loss among older adults, and the market for its treatments is substantial. Kodiak Sciences' stock price increased by 7.91 percent and 8.56 percent following the announcement.
What is confirmed
- Zenkuda and tabirafusp-ted achieved vision gains non-inferior to aflibercept at the one year mark in the phase III DAYBREAK trial.
- Kodiak Sciences' stock price increased by 7.91 percent and 8.56 percent following the announcement of the trial results.
Still unconfirmed
- Zenkuda could unlock significant growth opportunities through its multi-indication potential.
What to watch next
- Future regulatory decisions on Zenkuda's approval
- Detailed results from the phase III DAYBREAK trial
- Market reactions to Zenkuda's potential competition with existing wet AMD treatments
confidence 90%Sources used for this update (2)
- finance.yahoo.com — Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?
- www.metatrader.com — Can Zenkuda's Multi-Indication Potential Drive KOD Stock ...
-
Kodiak Sciences presents Phase III Zenkuda data at AAO 2026 meeting
Kodiak Sciences shared late stage clinical data for Zenkuda, tabirafusp-ted, and KSI-101 at the American Academy of Ophthalmology 2026 meeting in New Orleans. The Phase 3 DAYBREAK trial results show Zenkuda and tabirafusp-ted achieved vision gains non-inferior to aflibercept at the one year mark. These results place the pipeline in direct competition with the current standard of care for wet age-related macular degeneration. Market reactions include stock price increases of 7.91 percent and 8.56 percent as investors weigh the clinical efficacy and dosing intervals.
Why it matters
Wet age-related macular degeneration requires frequent injections of standard care drugs like aflibercept. Kodiak aims to reduce this burden by proving its therapies are equally effective while offering longer dosing intervals. Success in these trials is a prerequisite for regulatory approval and commercial viability.
What is confirmed
- Kodiak Sciences presented Phase 3 DAYBREAK, GLOW2, and Phase 1b APEX results at the American Academy of Ophthalmology 2026 meeting in New Orleans.
- Zenkuda and tabirafusp-ted achieved vision gains non-inferior to aflibercept at one year in the DAYBREAK trial.
Still unconfirmed
- Kodiak Sciences stock traded up by 7.91 percent following the trial data.
What to watch next
- Official regulatory filing dates for Zenkuda and tabirafusp-ted
- Detailed data release from the GLOW2 and APEX trials
confidence 90%Sources used for this update (2)
- simplywall.st — How Investors May Respond To Kodiak Sciences Stock After Wet ...
- www.timothysykes.com — KOD Stock Explodes As Zenkuda Trial Data Rewire Wall Street
-
Kodiak Sciences shares rise 8.56 percent following Phase III trial success
Kodiak Sciences shares increased by 8.56 percent as investors reacted to the Phase III DAYBREAK trial results for Zenkuda and tabirafusp-ted. The therapies met primary endpoints for wet age-related macular degeneration, proving non-inferiority and statistical equivalence to aflibercept. Clinical data showed retinal drying and vision gains, with 54 percent of patients achieving a six-month dosing interval. This progress has led to bullish analyst projections and significant insider buying as the company moves toward potential regulatory filings.
Why it matters
Wet age-related macular degeneration requires frequent injections to prevent vision loss. Zenkuda aims to reduce the treatment burden by extending the time between doses. Successful Phase III data is the final clinical hurdle before seeking FDA approval.
What is confirmed
- Kodiak Sciences shares traded up by 8.56 percent.
- Zenkuda and tabirafusp-ted met primary endpoints in the Phase III DAYBREAK trial for wet age-related macular degeneration.
- The therapies demonstrated statistical equivalence and non-inferiority to aflibercept.
- Fifty-four percent of patients reached a six-month dosing interval.
What to watch next
- FDA approval status and PDUFA dates
- Official partnership announcements
- Regulatory filing timelines for Zenkuda
confidence 100%Sources used for this update (4)
- stockstotrade.com — KOD Stock Soars As Zenkuda Trial Fuel Sparks Massive Re ...
- www.timothysykes.com — KOD Stock Rockets As DAYBREAK Trial Rewrites Biotech Expectations
- www.marketbeat.com — Kodiak Sciences (KOD) FDA Approvals, PDUFA Dates & Drug ...
- chartexchange.com — KOD News | ChartExchange
-
Kodiak Sciences soars on positive Phase III wet AMD trial results
Kodiak Sciences' shares surged after Zenkuda and tabirafusp-ted met primary endpoints in the Phase III DAYBREAK trial for wet age-related macular degeneration, demonstrating statistical equivalence and non-inferiority to aflibercept. The therapies showed vision gains and retinal drying, with 54% of patients reaching a six-month dosing interval. Analysts revised their projections bullishly, and insiders made substantial purchases.
Why it matters
The DAYBREAK trial results are significant for Kodiak Sciences as they bring the company closer to commercializing treatments for wet AMD, a leading cause of vision loss. The trial compared Zenkuda and tabirafusp-ted to aflibercept, a widely used treatment. Positive results could lead to regulatory submissions and potential market approval.
What is confirmed
- Zenkuda and tabirafusp-ted demonstrated statistical equivalence and non-inferiority to aflibercept in the Phase III DAYBREAK trial for wet AMD.
- 54% of patients in the trial reached a six-month dosing interval.
- Kodiak Sciences plans to present clinical data across all three of its late-stage assets at the American Academy of Ophthalmology Annual Meeting (AAO 2026).
Still unconfirmed
- Kodiak Sciences will bring Zenkuda data from five Phase 3 programs to regulators.
What to watch next
- Regulatory submissions for Zenkuda and tabirafusp-ted
- AAO 2026 presentations of detailed trial results
- Future updates on the commercialization timeline
confidence 85%Sources used for this update (15)
- kodiakcakes.com — Kodiak® | Feeding Epic Days & Wilder Lives™
- kodiak.com — Kodiak Sciences
- kodiakgas.com — Kodiak Gas Services - Contract Compression Services
- kodiakcakes.com — All Kodiak Products | Flapjacks, Waffles, Snacks & More |...
- en.wikipedia.org — Kodiak bear - Wikipedia
- en.wikipedia.org — Kodiak, Alaska - Wikipedia
- wne.edu — Kodiak for Students | Information Technology | WNE
- kodiakls.com — Skilled Staffing Solutions for Construction Projects
- finance.yahoo.com — Kodiak Sciences to Present Clinical Data Across All Three ...
- www.clinicaltrialvanguard.com — Kodiak Sciences to Report DAYBREAK Phase 3 Results for ...
- www.marketscreener.com — Kodiak Sciences Inc.: Official Announcements - Stock Market News
- marketchameleon.com — Kodiak Sciences spotlights three late-stage retina programs ...
-
Kodiak Sciences stock surges after Phase III wet AMD trial success
Kodiak Sciences shares rose over 162% by midday Monday after two drug candidates, Zenkuda and tabirafusp-ted, met primary endpoints in the Phase III DAYBREAK trial for wet age-related macular degeneration. The therapies demonstrated statistical equivalence and non-inferiority to aflibercept. Zenkuda, also known as tarcocimab tedromer, showed vision gains and retinal drying with a p-value of 0.0007. Notably, 54% of patients in the trial reached a six-month dosing interval. The results have led to bullish analyst revisions and substantial insider buying, though some valuation risks persist.
Why it matters
Wet AMD is a retinal disease requiring frequent eye injections. Zenkuda and tabirafusp-ted are designed to compete with Eylea, the current market standard. Success in this trial allows the company to move toward a Biologics License Application filing.
What is confirmed
- Zenkuda and tabirafusp-ted met primary endpoints in the Phase III DAYBREAK trial for wet age-related macular degeneration.
- Zenkuda, also known as tarcocimab tedromer, achieved a p-value of 0.0007.
- Both therapies demonstrated non-inferiority and statistical equivalence to aflibercept.
- 54% of patients in the vision trial went six months between eye treatments.
- Kodiak Sciences shares increased by over 162% by midday Monday.
Still unconfirmed
- Kodiak Sciences targets a Q4 BLA filing.
- Martin Shkreli claims the results still suck.
What to watch next
- Submission of the Biologics License Application (BLA)
- FDA review and approval decision for Zenkuda and tabirafusp-ted
confidence 100%Sources used for this update (17)
- Forbes — Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial
- Yahoo Finance — Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
- FirstWord — Kodiak surges on Phase III victory for Eylea rival in wet AMD
- Yahoo Finance — KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
- stocktitan.net — In a vision trial, 54% of patients went six months between eye treatments
- www.marketbeat.com — KOD News Today | Why did Kodiak Sciences stock go up today? $KOD
- finance.yahoo.com — Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary ...
- www.prnewswire.com — Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal ...
- www.proactiveinvestors.com — Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary ...
- allsci.com — Kodiak’s Zenkuda and tabirafusp-ted meet Phase III endpoints ...
- trial.medpath.com — Kodiak's Zenkuda and tabirafusp-ted hit primary endpoints in ...
- retinalphysician.com — DAYBREAK Meets Primary Endpoint in Wet AMD | Retinal Physician
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community